Type 2 Diabetes — Uncovering the 'ORIGINS' of Diabetes
Citation(s)
Aagaard-Tillery KM, Grove K, Bishop J, Ke X, Fu Q, McKnight R, Lane RH Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J Mol Endocrinol. 2008 Aug;41(2):91-102. doi: 10.1677/JME-08-0025. Epub 2008 May 30.
Cox J, Williams S, Grove K, Lane RH, Aagaard-Tillery KM A maternal high-fat diet is accompanied by alterations in the fetal primate metabolome. Am J Obstet Gynecol. 2009 Sep;201(3):281.e1-9. doi: 10.1016/j.ajog.2009.06.041.
Elia M, Livesey G Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. World Rev Nutr Diet. 1992;70:68-131. Review.
Henry RR, Abrams L, Nikoulina S, Ciaraldi TP Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects. Comparison using human skeletal muscle cell cultures. Diabetes. 1995 Aug;44(8):936-46.
Itani SI, Ruderman NB, Schmieder F, Boden G Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes. 2002 Jul;51(7):2005-11.
Moro C, Bajpeyi S, Smith SR Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity. Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E203-13. Epub 2007 Nov 14. Review.
Ptitsyn A, Hulver M, Cefalu W, York D, Smith SR Unsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome. BMC Genomics. 2006 Dec 19;7:318.
Shoelson SE, Lee J, Yuan M Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S49-52. Review.
Smith, S R., Martin, C., Katzmarzyk, P. & Church, T. Obesity and Diabetes: Implications for Management. in 2009 Educational Review Manual in Endocrinology FOCUS: Diabetes (ed. Kendall, D.M.) (Castle Connolly Graduate Medical Publishing, New York, NY 2009).
Sørlie T Introducing molecular subtyping of breast cancer into the clinic? J Clin Oncol. 2009 Mar 10;27(8):1153-4. doi: 10.1200/JCO.2008.20.6276. Epub 2009 Feb 9.
Sørlie T Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer. 2004 Dec;40(18):2667-75. Review.
van't Veer LJ, Bernards R Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008 Apr 3;452(7187):564-70. doi: 10.1038/nature06915. Review.
Wang S, Sparks LM, Xie H, Greenway FL, de Jonge L, Smith SR Subtyping obesity with microarrays: implications for the diagnosis and treatment of obesity. Int J Obes (Lond). 2009 Apr;33(4):481-9. doi: 10.1038/ijo.2008.277. Epub 2009 Feb 3.
Welch S, Gebhart SS, Bergman RN, Phillips LS Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab. 1990 Dec;71(6):1508-18.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.